Exelixis, Inc. (NASDAQ: EXEL) reported that its Executive Vice President and Chief Financial Officer, Christopher J. Senner, completed a series of sales of company stock between February 13 and February 17, selling 64,895 shares for approximately $2.8 million, according to a Form 4 filed with the U.S. Securities and Exchange Commission.
The filing indicates the trades were executed across multiple transactions at prices reported to range from $43.00 to $43.78. Specific entries on the Form 4 show varied pricing and purposes for the disposals.
On February 13, Senner sold 34,278 shares at a weighted average price of $43.00 per share, producing proceeds of $1,474,954. Two days later, on February 15, he disposed of 35,870 shares at $43.92 each for a total of $1,575,410; that sale was identified as covering taxes payable in connection with the vesting of performance-based restricted stock units. Finally, on February 17, Senner sold 30,617 shares at a weighted average price of $43.67 for proceeds of $1,336,044.
Altogether the transactions amount to the 64,895 shares noted in the filing and roughly $2.8 million in proceeds when combined.
Following these dispositions, the Form 4 reports that Senner directly owns 976,092 shares of Exelixis common stock. That direct ownership figure includes 427,690 shares scheduled to be issued upon the future vesting of restricted stock units and performance stock units granted on March 31, 2025. The filing also shows indirect ownership of 2,723 shares through the Exelixis, Inc. 401(k) Plan.
Company valuation and investment context appear in parallel to the insider transactions. InvestingPro data cited in the filing lists Exelixis’s market value at $11.57 billion and assigns an "Excellent" financial health rating, with a price-to-earnings ratio of 15.94.
Additionally, InvestingPro analysis mentioned alongside the filing suggests Exelixis may be trading at an attractive free cash flow yield of 8% and notes that management has been aggressively repurchasing shares. The company’s comprehensive Pro Research Report is identified as part of the InvestingPro coverage universe, which spans more than 1,400 U.S. equities.
The firm’s most recent reported quarterly results are also summarized in the filing material. Exelixis reported fourth-quarter 2025 earnings per share of $0.97, beating a consensus forecast of $0.80 by 21.25%. Revenue in the quarter totaled $598.66 million, which fell short of the $604.56 million projection.
Following those results, H.C. Wainwright adjusted its price target for Exelixis, moving it from $52.00 to $54.00 while maintaining a Buy rating; the firm cited lower-than-expected tax expenses as a material factor in the earnings beat. Separately, Citizens reaffirmed a Market Outperform rating and left a $50.00 price target in place, pointing to enthusiasm for Exelixis’s cancer therapy zanzalintinib, particularly for metastatic colorectal cancer. Citizens noted reinforcement of that view after discussions at the ESMO 2025 meeting, which highlighted the drug’s potential within the treatment landscape.
No additional commentary from company management or the insider was included in the filer’s Form 4. The filing provides a factual record of the trades, the post-transaction ownership stake, and the connections between share sales and tax obligations tied to equity vesting.